Due to the 12 month study run by MRK with very good results, suvo should get approved for chronic use. The GABAergics do not have such a label, so this should be an angle for reimbursement as well.
I just listened to the MRK conf call, so I will comment on what I heard in a subsequent post.
Market Data 
Markets 
AI
